By Fineline Cube 
Shanghai Escugen, a China-based clinical-stage company specializing in innovative antibody-drug conjugate (ADC) development, announced a strategic partnership with US-based SovranBio. The collaboration aims to accelerate the clinical development of multiple novel antibodies and ADCs by integrating SovranBio’s expertise in broad-spectrum target design with Escugen’s EZWi-Fit platform.
Collaboration Details
The partnership combines SovranBio’s innovative approach to targeting tumor antigens with Escugen’s advanced EZWi-Fit platform. This platform is recognized for its strong safety, efficacy, and resistance profiles. Research and development efforts, along with the benefits derived from this collaboration, will be jointly shared.
Escugen’s Pipeline and Technology
Escugen has advanced its core product, the Trop-2 ADC ESG401, into Phase III clinical trials. The EZWi-Fit platform has demonstrated significant potential, with its lead candidate already in human trials and additional licenses granted to several domestic and international partners.
SovranBio’s Focus
SovranBio is dedicated to pioneering novel approaches to cancer treatment, focusing on tumor antigens with potential pan-cancer applicability. Its pipeline includes solutions designed to address key challenges in disease intervention.-Fineline Info & Tech